These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 23737188)

  • 1. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.
    Al-Mansour Z; Nelson BP; Evens AM
    Curr Hematol Malig Rep; 2013 Sep; 8(3):173-83. PubMed ID: 23737188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-transplant lymphoproliferative disorders.
    Singavi AK; Harrington AM; Fenske TS
    Cancer Treat Res; 2015; 165():305-27. PubMed ID: 25655616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.
    Evens AM; Roy R; Sterrenberg D; Moll MZ; Chadburn A; Gordon LI
    Curr Oncol Rep; 2010 Nov; 12(6):383-94. PubMed ID: 20963522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations.
    Jagadeesh D; Woda BA; Draper J; Evens AM
    Curr Treat Options Oncol; 2012 Mar; 13(1):122-36. PubMed ID: 22241590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD; Preiksaitis JK;
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH; Russ GR; Coates PT
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M; Granai M; Bonzheim I; Steinhilber J; Schittenhelm J; Bethge W; Quintanilla-Martinez L; Fend F; Federmann B
    Virchows Arch; 2021 Jun; 478(6):1135-1148. PubMed ID: 33324999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How I treat posttransplant lymphoproliferative disorder.
    Amengual JE; Pro B
    Blood; 2023 Oct; 142(17):1426-1437. PubMed ID: 37540819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?
    Ranganathan S; Webber S; Ahuja S; Jaffe R
    Pediatr Dev Pathol; 2004; 7(4):348-60. PubMed ID: 14564542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation.
    Chen DB; Song QJ; Chen YX; Chen YH; Shen DH
    Int J Hematol; 2013 Jan; 97(1):117-24. PubMed ID: 23255160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant lymphoproliferative disorders.
    Dharnidharka VR; Webster AC; Martinez OM; Preiksaitis JK; Leblond V; Choquet S
    Nat Rev Dis Primers; 2016 Jan; 2():15088. PubMed ID: 27189056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases].
    Chen DB; Wang Y; Song QJ; Shen DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):607-12. PubMed ID: 23157829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL; Marcus R; Bradley JA
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options.
    Végso G; Hajdu M; Sebestyén A
    Pathol Oncol Res; 2011 Sep; 17(3):443-54. PubMed ID: 21193979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characteristics of post-transplant lymphoproliferative disorders.
    Nalesnik MA
    Recent Results Cancer Res; 2002; 159():9-18. PubMed ID: 11785849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant lymphoproliferative disorder.
    Everly MJ; Bloom RD; Tsai DE; Trofe J
    Ann Pharmacother; 2007 Nov; 41(11):1850-8. PubMed ID: 17940127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders.
    Choi JH; Park BB; Suh C; Won JH; Lee WS; Shin HJ
    J Korean Med Sci; 2010 Apr; 25(4):523-6. PubMed ID: 20357991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V; Siddiqi N; Kamaplath B; Chang CC; Cohen EP; Bresnahan BA; Hariharan S
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.